Treatment group | |||
---|---|---|---|
Parameter | Medical (n=213) | Revascularisation (n=65) | p Value |
Age, years | 63 (53, 71) | 68 (59, 78) | <0.01 |
Male | 74% | 80% | 0.30 |
Caucasian | 72% | 71% | 0.41 |
Hypertension | 67% | 79% | 0.08 |
Hyperlipidaemia | 70% | 69% | 0.91 |
Diabetes | 30% | 48% | 0.01 |
Peripheral vascular disease | 16% | 19% | 0.57 |
Prior myocardial infarction | 70% | 51% | 0.01 |
Prior percutaneous coronary intervention | 43% | 40% | 0.70 |
Prior coronary artery bypass grafting | 50% | 39% | 0.11 |
Prior revascularisation | 69% | 59% | 0.11 |
3-vessel disease | 54% | 57% | 0.63 |
Ejection fraction, % | 32 (26, 36) | 33 (28, 37) | 0.05 |
Prior smoking | 67% | 63% | 0.55 |
New York Heart Association class III–IV | 25% | 20% | 0.42 |
Charlson Index | 1 (0, 1) | 1 (0, 2) | 0.06 |
1 | 34% | 38% | 0.18 |
≥2 | 23% | 31% | |
Body mass index, kg/m2 | 27 (25, 31) | 28 (26, 32) | 0.07 |
Heart rate, bpm | 73 (64, 85) | 69 (61, 78) | 0.04 |
Systolic blood pressure, mm Hg | 132 (117, 149) | 144 (127, 167) | <0.01 |
β-Blocker | 52% | 51% | 0.85 |
ACE inhibitor | 62% | 66% | 0.60 |
Nitrate | 56% | 46% | 0.16 |
Statin | 25% | 44% | <0.01 |
Aspirin | 68% | 56% | 0.07 |
Calcium channel blocker | 16% | 28% | 0.05 |
Diuretic | 17% | 28% | 0.07 |
Represented as median (Q1, Q3) or % unless otherwise indicated.